tolmetin has been researched along with celecoxib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alexandova, A; Kesiova, M; Kirkova, M; Todorov, S | 1 |
| Bragg, RA; Bushby, N; Ellis-Sawyer, K; Elmore, CS; Hickey, MJ | 1 |
| Abdelall, EKA; Abdellatif, KRA; Fadaly, WAA; Labib, MB; Zidan, TH | 1 |
1 review(s) available for tolmetin and celecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for tolmetin and celecoxib
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Catalase; Celecoxib; Colon; Cyclooxygenase 2 Inhibitors; Diclofenac; Gastric Mucosa; Glucosephosphate Dehydrogenase; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glycine; Lipid Peroxidation; Liver; Male; Oxyphenonium; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Sulfhydryl Compounds; Sulfonamides; Thiobarbituric Acid Reactive Substances; Tolmetin | 2007 |
Isotope labelling by reduction of nitriles: Application to the synthesis of isotopologues of tolmetin and celecoxib.
Topics: Celecoxib; Chemistry Techniques, Synthetic; Isotope Labeling; Nitriles; Oxidation-Reduction; Tolmetin | 2017 |
Design, synthesis of celecoxib-tolmetin drug hybrids as selective and potent COX-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Gastric Mucosa; Humans; Indomethacin; Inflammation; Molecular Docking Simulation; Protein Binding; Rats; Tolmetin | 2019 |